AMPK signaling pathway
AMPK coordinates the response to fluctuating energy requirements in skeletal muscle, but it is not simply a switch between endurance and muscle building. Human studies show that AMPK markers, acute metabolic responses and long-term training adaptations should not be equated.
Auch bekannt als: AMPK, AMP-aktivierte Proteinkinase, Energiesensor
What it is
AMPK, the AMP-activated protein kinase, is a cellular energy sensor. In skeletal muscle, it helps to keep energy reserves stable when energy turnover changes by coordinating anabolic and catabolic processes. This means that it is part of a control network and not a universal switch that completely dismantles the structure and switches it on completely.
For classification, three levels must remain separate: the molecular activation state of AMPK, a physiological response such as glucose uptake, and a long-term outcome such as strength or muscle mass. A change at one level does not automatically prove a change at the next. An acute AICAR study on humans shows how clearly these levels can diverge.
How it works
Energy level and activation
The muscle-related overview classifies the binding of AMP and ADP to the gamma subunit as well as LKB1 and CaMKKβ as upstream kinases in the regulation. A central measurement point is the phosphorylation at Thr172. AMPK is thus regulated via several molecular inputs.
Coordination of metabolism
During exercise and recovery, AMPK is linked to substrate uptake, substrate oxidation, storage and mitochondrial function. This provides a plausible model for how muscle cells distribute fuel as needed. However, the overview is not a quantitative synthesis and does not assign a uniform effect size to these processes.
The common shorthand “AMPK on, mTORC1 and protein synthesis off” goes beyond these findings. Neither the mechanistic overview nor the human analysis evaluated trace a complete causal chain from AMPK through mTORC1 to long-term muscle hypertrophy. A possible molecular conflict is therefore not yet a proven training interference.
What the studies show
AICAR: glucose uptake without measured AMPK activation
In an acute study in 29 healthy men aged 26 ± 8 years with a BMI of 25 ± 4 kg/m², AICAR increased muscle 2-deoxyglucose uptake 2.1 ± 0.8-fold after three hours. A bicycle load increased it to 4.7 ± 1.7 times. With AICAR, whole-body glucose utilization increased by 7 percent, from 9.3 ± 0.6 to 10 ± 0.6 mg/kg/min.
At the same time, the measured activity of AMPK-α1 and AMPK-α2 as well as AMPK phosphorylation remained unchanged after 20 minutes and after three hours of AICAR. Bicycle exercise, on the other hand, increased AMPK phosphorylation.
The experiment thus shows an acute metabolic reaction, but no evidence that the measured AMPK activation caused this reaction. 2-Deoxyglucose intake is a metabolic endpoint and not a measurement of strength, endurance performance, or muscle growth. Which signaling pathway contributed to the effect of AICAR has not been fully understood.
Metformin: muscle concentration without significant AMPK effect
In a randomized crossover study in ten healthy, lean men, acute and four-day metformin treatment were examined. Peak concentrations were 31 micromolar in plasma and 11 micromolar in skeletal muscle. Despite this measured exposure, there was no significant treatment effect on AMPK activity in the muscle, neither at rest nor during exercise.
The measured plasma and muscle concentrations provide evidence of exposure but not an effective threshold. A direct comparison with the cell dose of the same activator is missing. There is also no study that jointly records dose, plasma and muscle concentrations, AMPK activity and long-term training adaptation. The concentrations alone therefore provide neither proof of mechanism nor performance.
During acute exercise, lactate, adrenaline, heart rate and subjectively perceived exertion were higher under metformin. The abstract does not provide any numerical effect sizes for these changes. The short examination shows a changed acute stress reaction, but neither a long-term loss of performance nor permanent damage.
Acute stress and twelve weeks of training
A secondary analysis of two randomized human trials included 29 people with impaired glucose tolerance and 15 healthy lean men. Acute stress and, in one of the studies, an additional twelve weeks of training were examined. Metformin did not significantly affect exercise- or training-related AMPK activation, mitochondrial respiration, and oxidative stress in muscle.
This null finding covers two populations and different time periods, but remains a secondary analysis of heterogeneous studies. Strength, muscle cross-section and endurance performance were not direct target endpoints. Genotypes, baseline values, and individual responder patterns have not been robustly tested or reported. A lack of a statistically significant mean effect therefore means “not shown” and does not rule out individual differences.
Dosage
- AMPK: AMPK is an endogenous signaling pathway and does not have a sports dosage. No target quantity for activation can be derived from its mechanistic function.
- AICAR and Metformin: Dose and route of intake are not reported in the abstracts evaluated. Therefore, no sports dosage and no safe transfer between the two interventions can be derived from these studies.
- Direct binding AMPK activators: Among the sources evaluated, there was no useful controlled human study over several weeks with strength, muscle cross-section or endurance performance in trained adults. A dosage for this purpose remains open.
- Berberine, cold and hypoxia: The sources evaluated link these approaches to AMPK signaling in human skeletal muscle and a performance endpoint in an uncontrolled manner. This does not result in a dosage recommendation.
Side effects
AMPK itself is an endogenous signaling pathway and not an administered substance. Therefore, no independent side effect profile of the signaling pathway can be derived from the mechanistic overview. Risks must be assessed based on the specific intervention and exposure.
Metformin under stress
Under metformin, lactate, adrenaline, heart rate and subjectively perceived exertion increased during acute exercise. The underlying mechanism was not determined in the data evaluated. The observation comes from a short treatment lasting one or four days; Dose and route of administration are not reported in the abstract.
Acute stress markers and perceived exertion were measured, not clinical events. Clinical limits, reversibility and long-term consequences have not been determined. Neither a proven countermeasure nor a concrete adjustment of the dose or route of intake can be derived from the study.
AICAR
The AICAR study documents an increased glucose intake with unchanged measured AMPK activity, but does not provide a reliable side effect profile from the data evaluated. The dose and route of administration are missing, and long-term consequences or clinical limits have not been studied. No countermeasure can be derived from this.
Classification
The muscle-related review describes AMPK as a regulator of energy balance, substrate utilization and mitochondrial function. The three human studies evaluated also show that an acute metabolic reaction can occur without measurable additional AMPK activation and that metformin does not have to show a statistically significant AMPK effect despite proven muscle concentration.
This only makes one narrow statement for training practice: From these four sources, neither an inevitable AMPK-related conflict between strength and endurance training nor its opposite can be derived. The review does not provide a chronic performance endpoint, and the 12-week human analysis did not test the sequence of combined training or AMPK-induced hypertrophy inhibition. These sources therefore do not provide a complete overview of the research field.
Pharmacological interventions are also not a clean replacement for a training experiment: under AICAR, glucose uptake increased without measurable AMPK activation. Metformin reached the muscle but did not show a significant AMPK effect in the short crossover study. In two further randomized studies, there was also no significant additional metformin effect on exercise- or training-related AMPK activation.
A crucial test would have to randomize trained adults over several weeks, confirm exposure in the muscle, measure the time course of the AMPK signal and at the same time record direct endpoints such as strength, muscle cross-section or endurance performance. If a targeted change in the signal shows a corresponding change in these endpoints under otherwise identical conditions, this would support the causal chain. Among the sources evaluated, there is no such controlled human study for directly binding AMPK activators.
This evidence base does not show that targeted AMPK activation in trained people improves endurance, inhibits muscle growth, or creates a causal conflict between strength and endurance training. It also remains unclear whether training status, baseline values or genotypes explain reproducible differences. The signaling pathway predicts what might happen. Direct endpoints must show whether it actually happens.
Sources
- Kjøbsted R et al. AMPK in skeletal muscle function and metabolism. FASEB J. 2018. PubMed
- Cuthbertson DJ et al. 5-aminoimidazole-4-carboxamide 1-beta-D-ribofuranoside acutely stimulates skeletal muscle 2-deoxyglucose uptake in healthy men. Diabetes. 2007. PubMed
- Kristensen JM et al. Metformin does not compromise energy status in human skeletal muscle at rest or during acute exercise: A randomised, crossover trial. Physiol Rep. 2019. PubMed
- Pilmark NS et al. Skeletal muscle adaptations to exercise are not influenced by metformin treatment in humans: secondary analyses of 2 randomized, clinical trials. Appl Physiol Nutr Metab. 2022. PubMed
This article was created using AI systems. Find out more